{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:22:09Z","timestamp":1771068129394,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.cgh.2017.11.038","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T04:15:58Z","timestamp":1511496958000},"page":"1616-1621.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Factors That Contribute to Indeterminate Results From the\u00a0QuantiFERON-TB Gold In-Tube Test in Patients With\u00a0Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8716-8882","authenticated-orcid":false,"given":"Manreet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-513X","authenticated-orcid":false,"given":"Prianka","family":"Singapura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeharika","family":"Kalakota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermina","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidra","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aylin","family":"Tansel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0084-5308","authenticated-orcid":false,"given":"Aaron P.","family":"Thrift","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hashem B.","family":"El-Serag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2017.11.038_bib1","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.11.038_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.11.038_bib3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10620-012-2371-5","article-title":"Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population","volume":"58","author":"Kappelman","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2017.11.038_bib4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A\u00a0short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.11.038_bib5","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.11.038_bib6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.11.038_bib7","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.11.038_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.11.038_bib9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.11.038_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn's disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.11.038_bib11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.11.038_bib12","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.11.038_bib13","unstructured":"Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2013California, 2002-2003. Washington, DC. Volume 2017, 2004."},{"key":"10.1016\/j.cgh.2017.11.038_bib14","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may\u00a0predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2017.11.038_bib15","unstructured":"American Gastroenterological Association. Adult Inflammatory Bowel Disease Physician Performance Measures Set. Bethesda, MD. Volume 2017,\u00a02011."},{"key":"10.1016\/j.cgh.2017.11.038_bib16","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment","volume":"60","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.cgh.2017.11.038_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based consensus on the prevention, diagnosis and\u00a0management of opportunistic infections in inflammatory bowel disease","volume":"3","author":"Rahier","year":"2009","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2017.11.038_bib18","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2016.10357","article-title":"Primary care screening and treatment for latent tuberculosis infection in adults: evidence report and systematic review for the US Preventive Services Task Force","volume":"316","author":"Kahwati","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2017.11.038_bib19","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMcp021045","article-title":"Clinical practice. Latent tuberculosis infection","volume":"347","author":"Jasmer","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.11.038_bib20","first-page":"49","article-title":"Guidelines for Using the QuantiFERON\u00ae-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States","volume":"54","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cgh.2017.11.038_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers\u00a0for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cgh.2017.11.038_bib22","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1111\/j.1572-0241.2008.02050.x","article-title":"Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease","volume":"103","author":"Schoepfer","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.11.038_bib23","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/acr.22454","article-title":"Evaluating indeterminate interferon-gamma-release assay results in patients with chronic inflammatory diseases receiving immunosuppressive therapy","volume":"67","author":"Calabrese","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cgh.2017.11.038_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon gamma release assay for latent tuberculosis\u00a0screening in patients with autoimmune diseases:\u00a0a systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.cgh.2017.11.038_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ibd.21329","article-title":"QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States","volume":"17","author":"Qumseya","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2017.11.038_bib26","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1097\/MIB.0000000000000147","article-title":"Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients","volume":"20","author":"Wong","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2017.11.038_bib27","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/ibd.22901","article-title":"Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"18","author":"Shahidi","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2017.11.038_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10238-012-0192-7","article-title":"Negative effect of immunosuppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases","volume":"13","author":"Ramos","year":"2013","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.cgh.2017.11.038_bib29","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/ibd.21605","article-title":"Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection","volume":"17","author":"Belard","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2017.11.038_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.crohns.2011.09.011","article-title":"Corticosteroids and\u00a0immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients","volume":"6","author":"Helwig","year":"2012","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2017.11.038_bib31","unstructured":"QuantiFERON\u00ae-TB Gold (In-Tube Method) [package insert]. Germantown, MD, QIAGEN Group, 2016."},{"key":"10.1016\/j.cgh.2017.11.038_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.tube.2015.02.039","article-title":"The impact of anti-tuberculous antibiotics and corticosteroids on cytokine production in QuantiFERON-TB Gold In Tube assays","volume":"95","author":"Clifford","year":"2015","journal-title":"Tuberculosis\u00a0(Edinb)"},{"key":"10.1016\/j.cgh.2017.11.038_bib33","doi-asserted-by":"crossref","first-page":"19972","DOI":"10.1038\/srep19972","article-title":"Effects of acute critical illnesses on the performance of interferon-gamma release assay","volume":"6","author":"Huang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2017.11.038_bib34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MPG.0000000000000205","article-title":"Disease activity is an important factor for indeterminate interferon-gamma release assay results in children with inflammatory bowel disease","volume":"58","author":"Hradsky","year":"2014","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2017.11.038_bib35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.0894-0959.2004.17603.x","article-title":"Serum albumin: relationship to inflammation and nutrition","volume":"17","author":"Don","year":"2004","journal-title":"Semin Dial"},{"key":"10.1016\/j.cgh.2017.11.038_bib36","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1128\/JCM.00814-14","article-title":"Extremes of age are associated with indeterminate QuantiFERON-TB gold assay results","volume":"52","author":"Tebruegge","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cgh.2017.11.038_bib37","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00296-014-3033-z","article-title":"Analysis of predictors influencing indeterminate whole-blood interferon-gamma release assay results in patients with rheumatic diseases","volume":"34","author":"Jung","year":"2014","journal-title":"Rheumatol Int"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517314118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517314118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:24:55Z","timestamp":1761542695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356517314118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1542356517314118"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2017.11.038","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors That Contribute to Indeterminate Results From the\u00a0QuantiFERON-TB Gold In-Tube Test in Patients With\u00a0Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2017.11.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the AGA Institute","name":"copyright","label":"Copyright"}]}}